VBIV insider filings
VBI Vaccines Inc/BC — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2023-07-31. Screen VBIV transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for VBIV between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — VBI Vaccines Inc/BC
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2023-07-31 | 4 | Braga Damian — Director | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2023-07-31 | 4 | DeWilde Michel — Director | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2023-07-28 | 4 | Dillman John Robert — Chief Commercial Officer | Grant/award (A): 52,500 (derivative) @ $0 | EDGAR |
| 2023-07-28 | 4 | Cordeiro Joanne — Director | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2023-07-28 | 4 | Mazaltov Avi — Head Global MFG&GM-SciVac Ltd. | Grant/award (A): 52,500 (derivative) @ $0 | EDGAR |
| 2023-07-28 | 4 | Beattie Nell — CFO, Head of Corp. Development, Director | Grant/award (A): 52,500 (derivative) @ $0 | EDGAR |
| 2023-07-28 | 4 | Diaz-Mitoma Francisco — Chief Medical Officer | Grant/award (A): 52,500 (derivative) @ $0 | EDGAR |
| 2023-07-28 | 4 | McKee Blaine H. — Director | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2023-07-28 | 4 | Anderson David Evander — Chief Scientific Officer | Grant/award (A): 52,500 (derivative) @ $0 | EDGAR |
| 2023-07-28 | 4 | Baxter Jeff — CEO, President, Director | Grant/award (A): 70,000 (derivative) @ $0 | EDGAR |
| 2023-07-28 | 4 | HIMES VAUGHN B — Director | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2023-07-28 | 4 | GILLIS STEVEN — Director | Grant/award (A): 52,500 (derivative) @ $0 | EDGAR |
| 2023-07-18 | 4 | GILLIS STEVEN — Director | Purchase (P): 609,090 @ $1.65 · Purchase (P): 609,090 (derivative) | EDGAR |
| 2023-04-28 | 4 | HIMES VAUGHN B — Director | Grant/award (A): 8,000 (derivative) @ $0 | EDGAR |
| 2023-04-06 | 4 | PERCEPTIVE ADVISORS LLC — 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD — 10% owner EDELMAN JOSEPH — 10% owner | Sale (S): 4,810,623 @ $0.16 · Sale (S): 1,832,563 @ $0.13 · Sale (S): 4,251,563 @ $0.11 | EDGAR |
| 2023-01-30 | 4 | Dillman John Robert — Chief Commercial Officer | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2023-01-30 | 4 | Braga Damian — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2023-01-30 | 4 | Cordeiro Joanne — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2023-01-30 | 4 | Mazaltov Avi — Head Global MFG&GM-SciVac Ltd. | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2023-01-30 | 4 | Beattie Nell — Chief Business Officer | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2023-01-30 | 4 | Diaz-Mitoma Francisco — Chief Medical Officer | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2023-01-30 | 4 | McNulty Christopher — CFO and Head of BD, Director | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2023-01-30 | 4 | McKee Blaine H. — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2023-01-30 | 4 | Anderson David Evander — Chief Scientific Officer | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2023-01-30 | 4 | Baxter Jeff — CEO, President, Director | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2023-01-30 | 4 | DeWilde Michel — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2023-01-30 | 4 | GILLIS STEVEN — Director | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2022-07-12 | 4 | Dillman John Robert — Chief Commercial Officer | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2022-01-31 | 4 | Braga Damian — Director | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2022-01-31 | 4 | Cordeiro Joanne — Director | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2022-01-31 | 4 | Mazaltov Avi — Head Global MFG&GM-SciVac Ltd. | Grant/award (A): 400,000 (derivative) @ $0 | EDGAR |
| 2022-01-31 | 4 | Beattie Nell — Chief Business Officer | Grant/award (A): 400,000 (derivative) @ $0 | EDGAR |
| 2022-01-31 | 4 | Diaz-Mitoma Francisco — Chief Medical Officer | Grant/award (A): 400,000 (derivative) @ $0 | EDGAR |
| 2022-01-31 | 4 | McNulty Christopher — CFO and Head of BD, Director | Grant/award (A): 400,000 (derivative) @ $0 | EDGAR |
| 2022-01-31 | 4 | McKee Blaine H. — Director | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2022-01-31 | 4 | Anderson David Evander — Chief Scientific Officer | Grant/award (A): 400,000 (derivative) @ $0 | EDGAR |
| 2022-01-31 | 4 | Baxter Jeff — CEO, President, Director | Grant/award (A): 800,000 (derivative) @ $0 | EDGAR |
| 2022-01-31 | 4 | DeWilde Michel — Director | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2022-01-31 | 4 | Bain Linda — Director | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2022-01-31 | 4 | GILLIS STEVEN — Director | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2021-12-06 | 4 | Beattie Nell — Chief Business Officer | Purchase (P): 8,200 @ $2.45 | EDGAR |
| 2021-12-03 | 4 | PERCEPTIVE ADVISORS LLC — 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD — 10% owner EDELMAN JOSEPH — 10% owner | Sale (S): 2,707,463 @ $3.31 | EDGAR |
| 2021-07-07 | 4 | Bain Linda — Director | Grant/award (A): 250,000 (derivative) @ $0 | EDGAR |
| 2021-06-30 | 4 | PERCEPTIVE ADVISORS LLC — 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD — 10% owner EDELMAN JOSEPH — 10% owner | Sale (S): 500,709 @ $3.80 · Sale (S): 145,548 @ $3.80 | EDGAR |
| 2021-06-11 | 4 | PERCEPTIVE ADVISORS LLC — 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD — 10% owner EDELMAN JOSEPH — 10% owner | Option exercise/expiry (X): 1,602,888 @ $2.75 · Option exercise/expiry (X): 465,936 @ $2.75 · Sale (S): 1,102,179 @ $4 · Sale (S): 320,388 @ $4 · Option exercise/expiry (X): 1,602,888 (derivative) @ $0 · Option exercise/expiry (X): 465,936 (derivative) @ $0 | EDGAR |
| 2021-02-01 | 4 | Mazaltov Avi — Head Global MFG&GM-SciVac Ltd. | Grant/award (A): 500,000 (derivative) @ $0 | EDGAR |
| 2021-02-01 | 4 | DeWilde Michel — Director | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2021-01-29 | 4 | Anderson David Evander — Chief Scientific Officer | Grant/award (A): 500,000 (derivative) @ $0 | EDGAR |
| 2021-01-29 | 4 | Baxter Jeff — CEO, President, Director | Grant/award (A): 1,000,000 (derivative) @ $0 | EDGAR |
| 2021-01-29 | 4 | GILLIS STEVEN — Director | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — VBI Vaccines Inc/BC
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2025-01-03 | 8-K | 2.01 — Completion of Acquisition or Disposition of Assets 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-12-10 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-08-02 | 8-K | 1.03 — Bankruptcy or Receivership 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-07-30 | 8-K | 1.03 — Bankruptcy or Receivership 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 2.04 — Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-06-25 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-05-29 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-05-24 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2024-05-15 | 8-K | 1.01 — Entry into a Material Definitive Agreement 1.02 — Termination of a Material Definitive Agreement 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-05-01 | 8-K | 8.01 — Other Events | EDGAR |
| 2024-04-16 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=VBIV returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs